Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors
20 Junho 2023 - 10:45AM
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”,
“Company”, “We” or “Us”), announced that effective today, Jeffrey
H. Cooper, former Chief Financial Officer of BioMarin
Pharmaceutical Inc., has been appointed to the Company’s Board of
Directors. Mr. Cooper brings significant leadership in finance,
accounting, strategy, and mergers & acquisitions to Nexcella.
After joining BioMarin in 2003, Mr. Cooper held positions of
increasing responsibility including Senior Vice President and Chief
Financial Officer from 2007 until 2012. In addition to his
experience at BioMarin, Mr. Cooper has served as an independent
director of Sierra Oncology, acquired by GlaxoSmithKline for $1.9
billion in 2022; and Tobira Therapeutics, acquired by Allergan (now
AbbVie) for $1.7 billion in 2016.
“We are thrilled to have Mr. Cooper join the Nexcella Board of
Directors. He possesses a wealth of experience as the CFO of
BioMarin and board member of other biotechnology firms which have
been acquired,” said Ilya Rachman, MD, Ph.D., Chief Executive
Officer of Immix Biopharma. Gabriel Morris, Chief Financial
Officer of Immix Biopharma, added: “Mr. Cooper’s 30 years of deep
experience in finance and capital markets of pharmaceutical
organizations will be an invaluable as we advance NXC-201 towards
US clinical trials and global applications for regulatory
approvals. We look forward to his contribution to our mission.”
“My decades of experience as a CFO and audit chair in the
pharmaceutical industry are a natural fit for Nexcella to further
enable bringing much needed cell therapies to patients,” said Mr.
Cooper. “I look forward to working with the Nexcella team to
advance its important technology to the next stage.”
During his career, Mr. Cooper served as Chief Financial Officer
of KaloBios Pharmaceuticals, Inc.; Vice President of Finance at
Matrix Pharmaceuticals; Corporate Controller at Foundation Health
Systems; and Director of Business Analysis at Syntex Corporation.
Mr. Cooper received a B.A. from the University of California, Los
Angeles and an M.B.A. from Santa Clara University. He was a
Certified Public Accountant (inactive status) in the state of
California through 2021.
About Nexcella, Inc.
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc
(Nasdaq:IMMX), is a Los Angeles, CA based clinical-stage
biopharmaceutical company engaged in the discovery and development
of novel cell therapies for oncology and other indications. Our
lead candidate, next generation BCMA-targeted CAR-T NXC-201 for
multiple myeloma and AL amyloidosis has produced 92% and 100%
response rates in each indication, respectively, as of February 9,
2023 across 58 patients. We believe NXC-201 has potential to be the
world’s first outpatient CAR-T. Our N-GENIUS platform allows us to
discover, develop, and manufacture cutting-edge cell therapies for
patients in need. To learn more about Nexcella, Inc. visit us at
www.nexcella.com.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a
clinical-stage biopharmaceutical company pioneering a novel class
of CAR-T cell therapies and Tissue-Specific Therapeutics (TSTx)
targeting oncology and immuno-dysregulated diseases with >75
patients treated to-date. Our lead cell therapy asset is NXC-201 in
multiple myeloma and AL Amyloidosis, which we believe could be the
world’s first out-patient CAR-T. Our lead TSTx asset IMX-110,
currently in Phase 1b/2a clinical trials as a monotherapy and
IMMINENT-01 combination clinical trial with BeiGene’s anti-PD-1
antibody tislelizumab, holds Orphan Drug Designation (ODD) and Rare
Pediatric Disease Designation (RPDD) by the FDA. ImmixBio
subsidiary Nexcella, Inc develops CAR-T NXC-201 for multiple
myeloma and AL amyloidosis, with 92% and 100% response rates in
each indication, respectively, as of February 9, 2023, currently
being trialed in NEXICART-1. Learn more at www.immixbio.com.
Forward Looking Statements
This press release contains “forward-looking statements”
Forward-looking statements reflect our current view about future
events. When used in this press release, the words “anticipate,”
“believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the
negative of these terms and similar expressions, as they relate to
us or our management, identify forward-looking statements. Such
statements, include, but are not limited to, statements contained
in this press release relating to our business strategy, our future
operating results and liquidity and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended or planned including: the uncertainties related
to market conditions and other factors described more fully in the
section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report
on Form 10-K for the year ended December 31, 2022, and other
periodic reports filed with the Securities and Exchange Commission.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Immix Biopharma, Inc.
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Factors or events that could cause our actual results to differ
may emerge from time to time, and it is not possible for us to
predict all of them. We cannot guarantee future results, levels of
activity, performance or achievements.
Contacts
Stern Investor RelationsAlex LoboManaging
DirectorAlex.lobo@sternir.com
Company Contact
irteam@immixbio.com
Immix Biopharma (NASDAQ:IMMX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Immix Biopharma (NASDAQ:IMMX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024